A Phase 2 interventional study of 146-9251 cream and Vehicle cream in Ichthyosis Vulgaris, sponsored by Crown Laboratories, Inc.. Completed at 7 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-08-10.
Sponsored by Crown Laboratories, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to determine and compare the safety and efficacy of topical 146-9251 cream and vehicle cream applied twice daily for 6 weeks in subjects with moderate to severe ichthyosis vulgaris (IV).
Crown Laboratories, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subject is pregnant, lactating, or is planning to become pregnant during the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Topical cream to be applied two times daily to specified treatment areas for 6 weeks.
Drug: 146-9251 cream
Topical cream to be applied two times daily to specified treatment areas for 6 weeks.
Drug: Vehicle cream
146-9251 cream contains an active drug and is applied topically.
Vehicle cream does not contain an active drug and is applied topically.
Treatment Success
Number of participants that show at least a 2 level improvement of overall severity of disease (as measured by IGA score) at 6 weeks. The IGA score is a static evaluation of the overall or "average" degree of severity of a participant's disease, taking into account all of the participant's scaling, erythema, and fissuring in the Treatment Area. IGA was assessed using the following 5-point scale: clear (0), almost clear (1), mild (2), moderate (3), or severe (4).
Time frame: Day 43 (6 weeks)
Adverse Events (AEs)
AEs will be assessed by the investigator and the number of participants with any local and systemic AEs will be reported.
Time frame: Day 0 through study completion, average 6 weeks, Day 43.
| Milestone | 146-9251 Cream | Vehicle Cream |
|---|---|---|
| Started | 40 | 40 |
| Completed | 36 | 38 |
| Not completed | 4 | 2 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 2 |
Number of participants that show at least a 2 level improvement of overall severity of disease (as measured by IGA score) at 6 weeks. The IGA score is a static evaluation of the overall or "average" degree of severity of a participant's disease, taking into account all of the participant's scaling, erythema, and fissuring in the Treatment Area. IGA was assessed using the following 5-point scale: clear (0), almost clear (1), mild (2), moderate (3), or severe (4).
| Participants | 146-9251 Cream | Vehicle Cream |
|---|---|---|
| Treatment Success | 21 | 28 |
AEs will be assessed by the investigator and the number of participants with any local and systemic AEs will be reported.
| Participants | 146-9251 Cream | Vehicle Cream |
|---|---|---|
| Number of Subjects with any AE | 9 | 14 |
| Number of Subjects without an AE | 31 | 26 |
Collected over AEs were collected from study day 1 to end of study (week 6).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 146-9251 Cream | 0/40 (0%) | 0/40 (0%) | 0/40 (0%) |
| Vehicle Cream | 0/40 (0%) | 0/40 (0%) | 5/40 (12.5%) |
| Event | 146-9251 Cream | Vehicle Cream |
|---|---|---|
| NasopharyngitisInfections and infestations | 0/40 | 5/40 |
Intent to treat (ITT) population defined as subjects who applied at least one dose of the assigned test article.
| Age, Continuous(years) | 146-9251 Cream | Vehicle Cream | Total |
|---|---|---|---|
| Mean | 54.8 ± 19.41 | 51.4 ± 17.42 | 53.1 ± 18.41 |
| Sex: Female, Male(Participants) | 146-9251 Cream | Vehicle Cream | Total |
|---|---|---|---|
| Female | 19 | 12 | 31 |
| Male | 21 | 28 | 49 |
| Ethnicity (NIH/OMB)(Participants) | 146-9251 Cream | Vehicle Cream | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 3 | 6 |
| Not Hispanic or Latino | 37 | 37 | 74 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 146-9251 Cream | Vehicle Cream | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 4 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 5 | 7 |
| White | 33 | 30 | 63 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Investigator's Global Assessment (IGA) Score(Participants) | 146-9251 Cream | Vehicle Cream | Total |
|---|---|---|---|
| 3-Moderate | 30 | 31 | 61 |
| 4-Severe | 10 | 9 | 19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2017 to primary completion in Apr 2019, 24 months.
Results were first posted in Jul 2021, 2 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ichthyosis Vulgaris